Benign Prostatic Hyperplasia Increases Long-term Chronic Kidney Disease Risk

Area of Science:

• Nephrology
• Urology
• Epidemiology

Background:

• Benign prostatic hyperplasia (BPH) is a common condition in aging men.
• Chronic kidney disease (CKD) is a significant public health concern.
• The relationship between BPH and CKD, including medication effects, requires further investigation.

Purpose of the Study:

• To evaluate the long-term association between benign prostatic hyperplasia (BPH) and the incidence of chronic kidney disease (CKD).
• To investigate the impact of BPH medications on the risk of CKD and end-stage kidney disease (ESKD).

Main Methods:

• Prospective cohort study utilizing UK Biobank data (2006-2010).
• Included 198,399 male participants without baseline CKD.
• Cox proportional hazards models analyzed BPH, its medication, and CKD/ESKD incidence.

Main Results:

• BPH diagnosis was associated with increased CKD risk (HR, 1.26; 95% CI, 1.10 to 1.45) after median 13.58-year follow-up.
• BPH medication use significantly elevated CKD risk in BPH patients (HR, 1.48; 95% CI, 1.18 to 1.85).
• A trend towards increased ESKD risk was observed in BPH patients (HR, 1.49; 95% CI, 0.72 to 3.08).

Conclusions:

• Patients with BPH exhibit a higher long-term risk for developing CKD.
• BPH medications are linked to an increased risk of CKD in individuals with BPH.
• Regular monitoring of kidney function is crucial for men diagnosed with BPH.